Development and validation of a high-throughput stereoselective LC–MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma

• Published in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Vol. 1017-1018; pp. 101 - 113
• Main Authors: Teitelbaum, Aaron M., Flaker, Alicia M., Kharasch, Evan D.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.04.2016
• Subjects: Antidepressive Agents, Second-Generation - blood; Assaying; Bupropion; Bupropion - analogs & derivatives; Bupropion - blood; Calibration; Chromatography; Chromatography, Liquid - methods; Enantiomers; Erythrohydrobupropion; Human; Humans; Hydroxybupropion; LC–MS/MS; Mass spectrometers; Metabolites; Quality Control; Separation; Sodium; Stereoselectivity; Tandem Mass Spectrometry - methods; Threohydrobupropion; Stereoselectivity; Threohydrobupropion; Bupropion; Erythrohydrobupropion; LC–MS/MS; Hydroxybupropion
• ISSN: 1570-0232; 1873-376X
• DOI: 10.1016/j.jchromb.2016.02.032

•A stereoselective analytical method for bupropion and metabolites was developed and validated on three triple quadrupole mass spectrometers.•Bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion enantiomers were resolved with a α1-acid glycoprotein chiral column.•Erythrohydrobupropion and threohydrobupropion enantiomer peaks were stereochemically assigned by borohydride reduction of enantiopure (R and S)-bupropion.•Plasma concentrations of bupropion and metabolite isomers were determined from a patient who received extended release (R,S)-bupropion. A stereoselective analytical method was developed and validated for the quantification of bupropion, and principle metabolites hydroxybupropion, erythrohydrobupropion and threohydrobupropion in human plasma. Separation of individual enantiomers (R)-bupropion, (S)-bupropion, (R,R)-hydroxybupropion, (S,S-hydroxybupropion), (1S,2S)-threohydrobupropion, (1R,2R)-threohydrobupropion, (1R,2S)-erythrohydrobupropion, and (1S,2R)-erythrohydrobupropion was achieved utilizing an α1-acid glycoprotein column within a 12-min run time. Chromatograph separation was significantly influenced by mobile phase pH and variability between columns. Analytes were quantified by positive ion electrospray tandem mass spectrometry following plasma protein precipitation with 20% trichloroacetic acid. Identification of erythrohydrobupropion enantiomer peaks and threohydrobupropion enantiomer peaks was achieved by sodium borohydride reduction of enantiopure (R)- and (S)-bupropion. Initial assay validation and sensitivity determination was on AB Sciex 3200, 4000 QTRAP, and 6500 mass spectrometers. Accuracy and precision were within 15% for each analyte. The assay was fully validated over analyte-specific concentrations using an AB Sciex 3200 mass spectrometer. Intra- and inter-assay precision and accuracy were within 12% for each analyte. The limits of quantification for bupropion (R and S), hydroxybupropion (R,R and S,S), threohydrobupropion (1S,2S and 1R,2R), and erythrohydrobupropion (1R,2S and 1S,2R) were 0.5, 2, 1, and 1ng/mL, respectively. All analytes were stable following freeze thaw cycles at −80°C and while stored at 4°C in the instrument autosampler. This method was applicable to clinical pharmacokinetic investigations of bupropion in patients. This is the first chromatographic method to resolve erythrohydrobupropion and threohydrobupropion enantiomers, and the first stereoselective LC–MS/MS assay to quantify bupropion, and principle metabolites hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.